The protein arginine methyltransferase PRMT1 ameliorates cerebral ischemia-reperfusion injury by suppressing RIPK1-mediated necroptosis and apoptosis.

Tengfei LIU; Gan HUANG; Xin GUO; Qiuran JI; Lu YU; Runzhe ZONG; Yiquan LI; Xiaomeng SONG; Qingyi FU; Qidi XUE; Yi ZHENG; Fanshuo ZENG; Ru SUN; Lin CHEN; Chengjiang GAO; Huiqing LIU

Return

The protein arginine methyltransferase PRMT1 ameliorates cerebral ischemia-reperfusion injury by suppressing RIPK1-mediated necroptosis and apoptosis.

Author: Tengfei LIU ¹ ; Gan HUANG ¹ ; Xin GUO ¹ ; Qiuran JI ¹ ; Lu YU ¹ ; Runzhe ZONG ¹ ; Yiquan LI ¹ ; Xiaomeng SONG ¹ ; Qingyi FU ¹ ; Qidi XUE ¹ ; Yi ZHENG ² ; Fanshuo ZENG ³ ; Ru SUN ⁴ ; Lin CHEN ¹ ; Chengjiang GAO ² ; Huiqing LIU ¹
Author Information

1. Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
2. Key Laboratory of Infection and Immunity of Shandong Province & Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
3. Department of Rehabilitation Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, China.
4. Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Publication Type:Journal Article
Keywords: Apoptosis; Arginine methylation; Cerebral ischemia–reperfusion injury; MLKL; Necroptosis; PRMT1; Phosphorylation; RIPK1
From: Acta Pharmaceutica Sinica B 2025;15(8):4014-4029
CountryChina
Language:English
Abstract: Receptor-interacting protein kinase 1 (RIPK1) plays an essential role in regulating the necroptosis and apoptosis in cerebral ischemia-reperfusion (I/R) injury. However, the regulation of RIPK1 kinase activity after cerebral I/R injury remains largely unknown. In this study, we found the downregulation of protein arginine methyltransferase 1 (PRMT1) was induced by cerebral I/R injury, which negatively correlated with the activation of RIPK1. Mechanistically, we proved that PRMT1 directly interacted with RIPK1 and catalyzed its asymmetric dimethylarginine, which then blocked RIPK1 homodimerization and suppressed its kinase activity. Moreover, pharmacological inhibition or genetic ablation of PRMT1 aggravated I/R injury by promoting RIPK1-mediated necroptosis and apoptosis, while PRMT1 overexpression protected against I/R injury by suppressing RIPK1 activation. Our findings revealed the molecular regulation of RIPK1 activation and demonstrated PRMT1 would be a potential therapeutic target for the treatment of ischemic stroke.